Last10K.com

Inhibikase Therapeutics, Inc. (IKT) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021

Inhibikase Therapeutics, Inc.

CIK: 1750149 Ticker: IKT
Document and Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2021
Mar. 14, 2022
Jun. 30, 2021
Cover [Abstract]   
Document Type10-K  
Amendment Flagfalse  
Document Period End DateDec. 31, 2021  
Document Fiscal Year Focus2021  
Document Fiscal Period FocusFY  
Trading SymbolIKT  
Entity Registrant NameINHIBIKASE THERAPEUTICS, INC.  
Entity Central Index Key0001750149  
Current Fiscal Year End Date--12-31  
Entity Filer CategoryNon-accelerated Filer  
Entity Well-known Seasoned IssuerNo  
Entity Current Reporting StatusYes  
Entity Voluntary FilersNo  
Entity Emerging Growth Companytrue  
Entity Small Businesstrue  
Entity Ex Transition Periodfalse  
ICFR Auditor Attestation Flagfalse  
Entity Shell Companyfalse  
Entity Common Stock, Shares Outstanding 25,227,051 
Entity Public Float  $ 51.4
Entity Tax Identification Number26-3407249  
Entity Interactive Data CurrentYes  
Document Annual Reporttrue  
Document Transition Reportfalse  
Security Exchange NameNASDAQ  
Documents Incorporated by Reference [Text Block]

None

  
Entity Address, Address Line One3350 Riverwood Parkway SE  
Entity Address, Address Line TwoSuite 1900  
Entity Address, City or TownAtlanta  
Entity Address, State or ProvinceGA  
Entity Address, Postal Zip Code30339  
City Area Code678  
Local Phone Number392-3419  
Entity Incorporation, State or Country CodeDE  
Title of 12(b) SecurityCommon Stock, $0.001 par value  
Entity File Number001-39676  
Auditor NameCohnReznick LLP  
Auditor Firm ID596  
Auditor LocationHolmdel, New Jersey  

View differences made from one year to another to evaluate Inhibikase Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Inhibikase Therapeutics, Inc..

Continue

Assess how Inhibikase Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Inhibikase Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Other
Filter Subcategory:
All
Cash Flow
Debt
Shares
Expense
Geography
Other
Inside Inhibikase Therapeutics, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations
Consolidated Statements Of Stockholders' Equity (Deficit)
Commitments And Contingencies
Commitments And Contingencies (Table)
Commitments And Contingencies - Additional Information (Details)
Commitments And Contingencies - Schedule Of Milestone Payment (Details)
Income Taxes
Income Taxes (Table)
Income Taxes - Additional Information (Details)
Income Taxes - Components Of Deferred Tax Assets And Liabilities (Details)
Income Taxes - Schedule Of Reconciliation Of Effective Income Tax Rate (Details)
Nature Of Business
Nature Of Business - Additional Information (Details)
Net Loss Per Share
Net Loss Per Share (Tables)
Net Loss Per Share - Summary Of Calculation Of Basic And Diluted Net Loss Per Share Applicable To Common Stockholders (Detail)
Net Loss Per Share - Summary Of Shares Excluded From Calculation Of Diluted Net Loss Per Share Applicable To Common Stockholders (Detail)
Notes Payable
Notes Payable (Table)
Notes Payable - Additional Information (Details)
Notes Payable - Summary Of Future Principal Payments On Notes Payable (Details)
Notes Payable - Summary Of Notes Payable (Details)
Simple Retirement Account For Employees (The "Simple Ira")
Simple Retirement Account For Employees (The "Simple Ira") - Additional Information (Details)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Additional Information (Details)
Stock-Based Compensation - Summary Of Estimated Assumptions Of Weighted-Average Fair Values Of Options Granted (Details)
Stock-Based Compensation - Summary Of Option Activity Under 2011 Plan And 2020 Plan (Details)
Stock-Based Compensation - Summary Of Stock-Based Compensation Expense For Stock Options Granted To Employees And Non-Employees (Details)
Stockholders' Deficit - Additional Information (Details)
Stockholders??? Deficit
Subsequent Events
Subsequent Events (Additional Information) (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies - Additional Information (Detail)
Supplemental Balance Sheet Information
Supplemental Balance Sheet Information (Tables)
Supplemental Balance Sheet Information - Schedule Of Accrued Expenses And Other Current Liabilities (Detail)
Warrants
Warrants - Additional Information (Details)
Ticker: IKT
CIK: 1750149
Form Type: 10-K Annual Report
Accession Number: 0000950170-22-005203
Submitted to the SEC: Thu Mar 31 2022 4:12:47 PM EST
Accepted by the SEC: Thu Mar 31 2022
Period: Friday, December 31, 2021
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ikt/0000950170-22-005203.htm